NSK-SD and Platelet and Red Blood Cell Aggregation

Platelet and Red Blood Cell Aggregation Inhibiting Effect

We have 3 human clinical studies that show NSK-SD can help prevent platelet aggregation and red blood cell aggregation in blood.

  • Jang et al. 2013 - In a rodent study, nattokinase displayed excellent anti-platelet aggregation and anti-thrombotic activities in vitro and in vivo. It is suggested that nattokinase could be a good health functional food for the improvement of blood flow.

  • Takaoka 2003 - In 10 healthy adults, NSK-SD showed inhibitory effects on platelet aggregation with peak mostly at 6hrs, 4 patients saw up to a 50% decrease.

  • Takaoka 2004 - In 9 smokers or subjects with hyperlipidemia (individuals at risk from spontaneous platelet aggregation), strong inhibitory effect on spontaneous platelet aggregation after 6 hours from administration of NSK-SD was observed. The rate of small aggregates increased and medium and large aggregates decreased, which shows NSK-SD may have inhibited the small aggregates from forming into larger aggregates.

  • Pais 2006 - In an in-vitro study, 17 to 125 FU/ml of nattokinase was incubated with blood samples. Results showed a dose-dependent decrease of RBC aggregate sizes from the control ranging from 22% to 62% inhibition of red blood cell aggregation respectively.

  • Human study on 2 subjects with Rouleaux formation (red blood cell stacking). One subject was a smoker male and one was a non-smoker female. 2,000FU/day of NSK-SD softgels were administered for 7 days. Treatment returned the red blood cells close to normal after 1 week and the rouleaux formation did not begin again until after 3 weeks after discontinuation of treatment.

Screen Shot 2020-07-14 at 3.46.38 PM.png
Screen Shot 2020-07-14 at 3.42.38 PM.png